ROCKVILLE, MD -- Celera Genomics (NYSE:CRA), an Applera Corporation business, announced it signed a memorandum of understanding with the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The memorandum of understanding outlines the terms and conditions under which individual NCI principal investigators may elect whether or not to purchase access to Celera's analytical tools and database products, including the fruit fly, human, and mouse genomes. The subscribers will access Celera's database information through the Celera Discovery System. The Celera Discovery System is an integrated, web-based platform that enables users to leverage Celera's computational tools, super-computing power, and genomic and biological data to advance the discovery process for researchers worldwide. Applera Corporation’s Celera Genomics Group, headquartered in Rockville, MD, intends to be a definitive source of genomic and related medical information. Celera has developed three business units: the On-line Information Business, Discovery Sciences, and Discovery Services, all of which build upon Celera's generation, integration, and analysis of biological information. Celera intends to enable therapeutic discoveries both through its own application of its scientific capabilities and in partnership with pharmaceutical and biotechnology companies.